Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) and ADC technologies for the treatment of cancers.
H.B. Fuller Company, the biggest pureplay adhesives company in the world, has acquired ND Industries, a leading provider of specialty adhesives and fastener locking and sealing solutions serving customers in the automotive, electronics, aerospace, and other industries.
US specialty chemicals producer Ashland has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions. Financial details of the transaction were not given.
Ineos Oxide and LyondellBasell have completed the sale of LyondellBasell’s Ethylene Oxide & Derivatives (EO&D) business and associated production facilities located in Bayport, Texas to Ineos.
Swiss drugmaker Novartis agreed to acquire Mariana Oncology, a US biotechnology company based in Watertown, Massachusetts, that develops novel radioligand therapies (RLTs) for the treatment of cancer.
Japan’s Ono Pharmaceutical agreed to acquire US cancer-therapy company Deciphera Pharmaceuticals for approximately $2.4 billion. Deciphera focuses on innovative cancer therapeutics, and specializes in kinase biology.
Arkema agreed to acquire Dow’s flexible packaging laminating adhesives business, a leading producer in this market with annual sales of approximately $250 million (€233 million). This acquisition will expand Arkema’s flexible packaging solutions portfolio, positioning the group as a key player in the industry.
Syensqo announced the acquisition of JinYoung Bio, a specialty cosmetic ingredients supplier based in South Korea. This investment expands Syensqo’s portfolio toward more natural and high-value specialty skin care solutions with functional and active ingredients.
Kühne Holding has agreed to purchase Aenova Group, a pharma contract development and manufacturing organization (CDMO), from BC Partners. BC will reinvest and retain a minority stake in Aenova. The financial terms remain undisclosed.
Saudi Arabia’s state-owned oil giant Aramco has entered into discussions with Hengli Group regarding the potential acquisition of a 10% stake in Hengli Petrochemical, subject to due diligence and required regulatory clearances.
Sumitomo Chemical has announced to divest all of its shares in two of its flat panel display (FPD) process chemical subsidiaries in China to Zhenjiang Runjing High Purity Chemical Technology (Runjing Tech). The transaction is expected to be completed by the end of May this year. Financial details of the transaction were not disclosed.
Arkema is set to acquire a 78% stake in Proionic, a start-up specializing in ionic liquids production. These components are crucial for future lithium-ion batteries. This acquisition expands Arkema’s solutions and strengthens its position in the materials sector across various battery technologies.
Following regulatory approval of the deal, Italian chemical company Versalis has completed the acquisition of compounder Tecnofilm.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
DKSH has announced the signing of an agreement to acquire Malaysia's Elite Organic Sdn. Bhd. This acquisition allows DKSH Performance Materials to enhance its capabilities in the promising pharmaceutical, food, and nutraceutical markets across the Asia Pacific region.
German distribution giant Brenntag announced the acquisition of Lawrence Industries, an independent specialties distributor in the UK. The transaction, Brenntag said, further strengthens the company’s position within Material Science and across the coatings, adhesives, sealants and elastomers (CASE), construction, polymer and rubber industries. Financial details of the deal were not disclosed.
Azelis continues its acquisition spree, this time adding Indonesian distributor PT Marga Dwi Kencana (MDK) to its portfolio. Financial details of the deal were not disclosed.
Danish drugmaker Genmab has agreed to buy privately-owned US biotechnology company ProfoundBio for $1.8 billion. ProfoundBio develops novel ADCs and ADC technologies for the treatment of certain cancers, including ovarian cancer and other FRα-expressing solid tumors.
Clariant, a specialty chemical company, announced it has completed the acquisition of Lucas Meyer Cosmetics, a provider of high-value ingredients for the cosmetics and personal care industry, from IFF for an Enterprise Value (EV) of $810 million (€746 million). The purchase price will be subject to customary net debt and working capital adjustments.
Swiss construction chemicals major Sika has acquired Kwik Bond Polymers (KBP), a US-based manufacturer of polymer systems for the refurbishment of concrete infrastructure. Financial details of the transaction were not disclosed.
Ineos has completed the acquisition of Naphtachimie, Gexaro and Appryl, which were 50:50 Joint Ventures between Ineos and TotalEnergies at Lavera in Southern France.
Novo Nordisk is to acquire Cardior Pharmaceuticals for up to €1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved.
UK’s Johnson Matthey (JM) has signed a definitive agreement to sell 100% of its Medical Device Components (MDC) business to Montagu Private Equity for $700 million (£550 million).
AstraZeneca has agreed to acquire Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).
Roquette, a plant-based ingredients and pharmaceutical excipients manufacturer, announced today an agreement to acquire IFF Pharma Solutions, an excipients for oral dosage solutions producer, to reinforce its position as a major partner to the pharmaceutical industry.
Britain's AstraZeneca is to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases, more than $1 billion.
US specialty materials producer Trinseo has commenced a sale process for its 50% ownership in Americas Styrenics (AmSty), a joint venture (JV) with Chevron Phillips Chemical.
In a move to expand its ophthalmic platform, Sandoz, the former generics and biosimilars arm of Swiss drugmaker Novartis, has completed the acquisition of Coherus BioSciences’ subsidiary Coherus Ophthalmology for $170 million.
Swedish chemical producer Perstorp has bought out its minority partner in the joint venture (JV) Shandong Perstorp Chemical Co. (formerly Shandong Fufeng Perstorp Chemical Co.), which has owned and operated the site in China. Perstorp is now the sole owner of the polyol manufacturing operation, located in Zibo, Shandong province.
Abu Dhabi National Oil Company (ADNOC) has completed the acquisition of a 24.9% stake in Austrian energy group OMV from Mubadala, the sovereign wealth fund of the United Arab Emirates. Financial details of the transaction, which was announced in December 2022, were not disclosed.
ICL is to acquired Nitro 1000, a Brazilian manufacturer, developer and provider of biologicals for approximately $30 million.
Within a few days, Anglo-Swedish drugmaker AstraZeneca has completed the acquisitions of Gracell Biotechnologies and Icosavax. Both transactions were announced in December 2023.
NextChem, part of Italian engineering group Maire Tecnimont, has signed a binding agreement to acquire 80% of HyDEP and 100% of Dragoni Group for a total of approximately €3.6 million.
Olefins and polyolefins giant LyondellBasell (LYB) has acquired mechanical recycling assets containing rigid plastics recycling processing lines in the US from PreZero, a recycling and waste management service provider. The transaction, LYB said, includes the lease of the processing facility in Jurupa Valley, California, with a production capacity of approx. 23 million kg/year for recycled materials.
US biopharmaceutical company Gilead Sciences is to acquire CymaBay Therapeutics for $4.3 billion. Gilead offered to purchase all outstanding shares of CymaBay for $32.50 per share in cash.
